Breast cancer is able to modify the lymphatic vessels through which it travels to the draining lymph nodes. From there, it can then spread to other parts of the body. A new finding by Finnish researchers may help develop targeted therapies that could prevent this spread.

Recently, a review article by the research teams led by Professor Chen Shiyi from Huashan Hospital, Professor Dai Li Hua from the Affiliated City Dong Hospital, and Director Wu Guanghui from the Affiliated Ningde Hospital was published in the renowned journal Research. The study emphasizes how robotic exoskeletons can significantly improve cancer patients' mobility, muscle strength, and gait training, while also contributing to psychological recovery through personalized support and real-time feedback. This innovation is poised to reshape the future of cancer rehabilitation.

Rice bioengineers have designed an erasable serum marker that could enable clinicians to detect problems or measure any changes in how a patient responds to treatment with greater precision, using simple, minimally-invasive testing.

New Houston Methodist research has revealed that a protein associated with neurodegenerative diseases such as dementia and amyotrophic lateral sclerosis (ALS) also plays a role in regulating DNA mismatch repair, a process essential for replicating genetic information and cell health. The finding could change how scientists understand both cancer and neurodegeneration.

Cambridge, MA — 12/02/2025 — Insilico Medicine (“Insilico”), a global leader in AI-powered drug discovery, and Atossa Therapeutics (“Atossa”) (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments for breast cancer and other serious conditions, announce the publication of a joint study evaluating the potential of (Z)-endoxifen for glioblastoma multiforme (GBM). The peer-reviewed article, now published in Nature’s Scientific Reports, represents one of the most comprehensive AI-enabled analyses to date exploring whether endoxifen, an active metabolite of tamoxifen with known activity in endocrine-resistant breast cancer, may offer new therapeutic opportunities for one of the deadliest malignant brain tumors in adults. The study aimed to identify new oncology indications with high therapeutic potential for endoxifen, as monotherapy or in combination, by applying Insilico’s AI-powered PandaOmics platform across a wide range of cancer types based on its mechanisms of action. Through this systematic evaluation, GBM emerged as a top candidate for further investigation.